首页 > 最新文献

Emerging Microbes & Infections最新文献

英文 中文
In vivo rescue of arboviruses directly from subgenomic DNA fragments. 直接从亚基因组 DNA 片段对虫媒病毒进行活体解救。
IF 13.2 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2024-05-26 DOI: 10.1080/22221751.2024.2356140
Maxime Cochin, Jean-Sélim Driouich, Grégory Moureau, Géraldine Piorkowski, Xavier de Lamballerie, Antoine Nougairède

Reverse genetic systems are mainly used to rescue recombinant viral strains in cell culture. These tools have also been used to generate, by inoculating infectious clones, viral strains directly in living animals. We previously developed the "Infectious Subgenomic Amplicons" (ISA) method, which enables the rescue of single-stranded positive sense RNA viruses in vitro by transfecting overlapping subgenomic DNA fragments. Here, we provide proof-of-concept for direct in vivo generation of infectious particles following the inoculation of subgenomic amplicons. First, we rescued a strain of tick-borne encephalitis virus in mice to transpose the ISA method in vivo. Subgenomic DNA fragments were amplified using a 3-fragment reverse genetics system and inoculated intramuscularly. Almost all animals were infected when quantities of DNA inoculated were at least 20 µg. We then optimized our procedure in order to increase the animal infection rate. This was achieved by adding an electroporation step and/or using a simplified 2- fragment reverse genetics system. Under optimal conditions, a large majority of animals were infected with doses of 20 ng of DNA. Finally, we demonstrated the versatility of this method by applying it to Japanese encephalitis and Chikungunya viruses. This method provides an efficient strategy for in vivo rescue of arboviruses. Furthermore, in the context of the development of DNA-launched live attenuated vaccines, this new approach may facilitate the generation of attenuated strains in vivo. It also enables to deliver a substance free of any vector DNA, which seems to be an important criterion for the development of human vaccines.

反向遗传系统主要用于挽救细胞培养中的重组病毒株。我们之前开发了 "感染性亚基因组扩增子"(ISA)方法,通过转染重叠的亚基因组 DNA 片段在体外挽救单链正义 RNA 病毒。在这里,我们提供了接种亚基因组扩增子后在体内直接产生感染性颗粒的概念验证。首先,我们在小鼠体内拯救了一株蜱传脑炎病毒,在体内转染 ISA 方法。使用 3 片段反向遗传学系统扩增亚基因组 DNA 片段,并将其肌肉注射到动物体内。当接种的 DNA 数量至少为 20µg 时,几乎所有动物都受到了感染。随后,我们对程序进行了优化,以提高动物感染率。为此,我们增加了电穿孔步骤和/或使用简化的 2 片段反向遗传系统。在最佳条件下,绝大多数动物的 DNA 感染剂量为 20ng。最后,我们将这种方法应用于日本脑炎和基孔肯雅病毒,证明了它的多功能性。此外,在开发 DNA 发射减毒活疫苗的背景下,这种新方法可促进体内减毒株的产生。它还能提供不含任何载体 DNA 的物质,这似乎是开发人类疫苗的一个重要标准。
{"title":"<i>In vivo</i> rescue of arboviruses directly from subgenomic DNA fragments.","authors":"Maxime Cochin, Jean-Sélim Driouich, Grégory Moureau, Géraldine Piorkowski, Xavier de Lamballerie, Antoine Nougairède","doi":"10.1080/22221751.2024.2356140","DOIUrl":"10.1080/22221751.2024.2356140","url":null,"abstract":"<p><p>Reverse genetic systems are mainly used to rescue recombinant viral strains in cell culture. These tools have also been used to generate, by inoculating infectious clones, viral strains directly in living animals. We previously developed the \"Infectious Subgenomic Amplicons\" (ISA) method, which enables the rescue of single-stranded positive sense RNA viruses <i>in vitro</i> by transfecting overlapping subgenomic DNA fragments. Here, we provide proof-of-concept for direct <i>in vivo</i> generation of infectious particles following the inoculation of subgenomic amplicons. First, we rescued a strain of tick-borne encephalitis virus in mice to transpose the ISA method <i>in vivo</i>. Subgenomic DNA fragments were amplified using a 3-fragment reverse genetics system and inoculated intramuscularly. Almost all animals were infected when quantities of DNA inoculated were at least 20 µg. We then optimized our procedure in order to increase the animal infection rate. This was achieved by adding an electroporation step and/or using a simplified 2- fragment reverse genetics system. Under optimal conditions, a large majority of animals were infected with doses of 20 ng of DNA. Finally, we demonstrated the versatility of this method by applying it to Japanese encephalitis and Chikungunya viruses. This method provides an efficient strategy for <i>in vivo</i> rescue of arboviruses. Furthermore, in the context of the development of DNA-launched live attenuated vaccines, this new approach may facilitate the generation of attenuated strains <i>in vivo</i>. It also enables to deliver a substance free of any vector DNA, which seems to be an important criterion for the development of human vaccines.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":13.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11133884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistant Candida auris. 兰索拉唑可干扰真菌呼吸,并与两性霉素 B 协同作用,共同对抗耐多药念珠菌。
IF 13.2 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2024-03-03 DOI: 10.1080/22221751.2024.2322649
Ehab A Salama, Yehia Elgammal, Aruna Wijeratne, Nadia A Lanman, Sagar M Utturkar, Atena Farhangian, Jianing Li, Brigitte Meunier, Tony R Hazbun, Mohamed N Seleem

Candida auris has emerged as a problematic fungal pathogen associated with high morbidity and mortality. Amphotericin B (AmB) is the most effective antifungal used to treat invasive fungal candidiasis, with resistance rarely observed among clinical isolates. However, C. auris possesses extraordinary resistant profiles against all available antifungal drugs, including AmB. In our pursuit of potential solutions, we screened a panel of 727 FDA-approved drugs. We identified the proton pump inhibitor lansoprazole (LNP) as a potent enhancer of AmB's activity against C. auris. LNP also potentiates the antifungal activity of AmB against other medically important species of Candida and Cryptococcus. Our investigations into the mechanism of action unveiled that LNP metabolite(s) interact with a crucial target in the mitochondrial respiratory chain (complex III, known as cytochrome bc1). This interaction increases oxidative stress within fungal cells. Our results demonstrated the critical role of an active respiratory function in the antifungal activity of LNP. Most importantly, LNP restored the efficacy of AmB in an immunocompromised mouse model, resulting in a 1.7-log (∼98%) CFU reduction in the burden of C. auris in the kidneys. Our findings strongly advocate for a comprehensive evaluation of LNP as a cytochrome bc1 inhibitor for combating drug-resistant C. auris infections.

白色念珠菌已成为一种棘手的真菌病原体,发病率和死亡率都很高。两性霉素 B(AmB)是治疗侵袭性真菌念珠菌病最有效的抗真菌药物,临床分离株很少出现耐药性。然而,念珠菌对包括两性霉素 B 在内的所有现有抗真菌药物都具有极强的耐药性。为了寻求潜在的解决方案,我们筛选了 727 种美国食品及药物管理局批准的药物。我们发现质子泵抑制剂兰索拉唑(LNP)能有效增强 AmB 对阿氏杆菌的活性。LNP 还能增强 AmB 对其他重要医学念珠菌和隐球菌的抗真菌活性。我们对其作用机制的研究发现,LNP 代谢物与线粒体呼吸链(复合体 III,即细胞色素 bc1)中的一个关键靶点相互作用。这种相互作用增加了真菌细胞内的氧化应激。我们的研究结果表明,活跃的呼吸功能在 LNP 的抗真菌活性中起着关键作用。最重要的是,LNP 恢复了 AmB 在免疫功能低下小鼠模型中的疗效,使肾脏中的阴沟肠杆菌负担减少了 1.7 个菌落(∼98%)。我们的研究结果强烈建议将 LNP 作为细胞色素 bc1 抑制剂进行全面评估,以抗击耐药性蛔虫感染。
{"title":"Lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistant <i>Candida auris</i>.","authors":"Ehab A Salama, Yehia Elgammal, Aruna Wijeratne, Nadia A Lanman, Sagar M Utturkar, Atena Farhangian, Jianing Li, Brigitte Meunier, Tony R Hazbun, Mohamed N Seleem","doi":"10.1080/22221751.2024.2322649","DOIUrl":"10.1080/22221751.2024.2322649","url":null,"abstract":"<p><p><i>Candida auris</i> has emerged as a problematic fungal pathogen associated with high morbidity and mortality. Amphotericin B (AmB) is the most effective antifungal used to treat invasive fungal candidiasis, with resistance rarely observed among clinical isolates. However, <i>C. auris</i> possesses extraordinary resistant profiles against all available antifungal drugs, including AmB. In our pursuit of potential solutions, we screened a panel of 727 FDA-approved drugs. We identified the proton pump inhibitor lansoprazole (LNP) as a potent enhancer of AmB's activity against <i>C. auris.</i> LNP also potentiates the antifungal activity of AmB against other medically important species of <i>Candida</i> and <i>Cryptococcus.</i> Our investigations into the mechanism of action unveiled that LNP metabolite(s) interact with a crucial target in the mitochondrial respiratory chain (complex III, known as cytochrome <i>bc<sub>1</sub></i>). This interaction increases oxidative stress within fungal cells. Our results demonstrated the critical role of an active respiratory function in the antifungal activity of LNP. Most importantly, LNP restored the efficacy of AmB in an immunocompromised mouse model, resulting in a 1.7-log (∼98%) CFU reduction in the burden of <i>C. auris</i> in the kidneys. Our findings strongly advocate for a comprehensive evaluation of LNP as a cytochrome <i>bc<sub>1</sub></i> inhibitor for combating drug-resistant <i>C. auris</i> infections.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":13.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influenza D virus infection in China, 2022-2023. 2022-2023 年中国 D 型流感病毒感染情况。
IF 13.2 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2024-05-15 DOI: 10.1080/22221751.2024.2343907
Jieshi Yu, Zhenyu Wen, Wanke Hu, Mingwang Chen, Yuanlong Zhang, Shasha Liu, Gang Wang, Zhao Wang, Dan Wang, Shao-Lun Zhai, Wen-Kang Wei, Tianyu Li, Ming Liao

Influenza D virus (IDV) plays an important role in the bovine respiratory disease (BRD) complex. Its potential for the zoonotic transmission is of particular concern. In China, IDV has previously been identified in agricultural animals by molecular surveys with no live virus isolates reported. In this study, live IDVs were successfully isolated from cattle in China, which prompted us to further investigate the national prevalence, antigenic property, and infection biology of the virus. IDV RNA was detected in 11.1% (51/460) of cattle throughout the country in 2022-2023. Moreover, we conducted the first IDV serosurveillance in China, revealing a high seroprevalence (91.4%, 393/430) of IDV in cattle during the 2022-2023 winter season. Notably, all the 16 provinces from which cattle originated possessed seropositive animals, and 3 of them displayed the 100% IDV-seropositivity rate. In contrast, a very low seroprevalence of IDV was observed in pigs (3%, 3/100) and goats (1%, 1/100) during the same period of investigation. Furthermore, besides D/Yama2019 lineage-like IDVs, we discovered the D/660 lineage-like IDV in Chinese cattle, which has not been detected to date in Asia. Finally, the Chinese IDVs replicated robustly in diverse cell lines but less efficiently in the swine cell line. Considering the nationwide distribution, high seroprevalence, and appreciably genetic diversity, further studies are required to fully evaluate the risk of Chinese IDVs for both animal and human health in China, which can be evidently facilitated by IDV isolates reported in this study.

D 型流感病毒(IDV)在牛呼吸道疾病(BRD)中扮演着重要角色。它的人畜共患传播潜力尤其令人担忧。在中国,以前曾通过分子调查在农业动物中发现过 IDV,但没有分离到活体病毒的报道。本研究成功地从中国的牛体内分离到了活体 IDV,这促使我们进一步研究该病毒在全国的流行情况、抗原特性和感染生物学特性。2022-2023 年,在全国 11.1%(51/460)的牛中检测到 IDV RNA。此外,我们在中国首次开展了IDV血清监测,发现2022-2023年冬季牛的IDV血清流行率很高(91.4%,393/430)。值得注意的是,所有 16 个牛来源省份均有血清阳性动物,其中 3 个省份的 IDV 血清阳性率达到 100%。相比之下,在同一调查期间,猪(3%,3/100)和山羊(1%,1/100)的 IDV 血清阳性率非常低。此外,除了 D/Yama2019 系类 IDV 外,我们还在中国牛群中发现了 D/660 系类 IDV,这是迄今为止在亚洲尚未发现的。最后,中国的 IDV 在不同细胞系中的复制能力很强,但在猪细胞系中的复制效率较低。考虑到中国IDV在全国范围内的分布、高血清流行率和显著的遗传多样性,需要进一步研究以全面评估中国IDV对中国动物和人类健康的风险。
{"title":"Influenza D virus infection in China, 2022-2023.","authors":"Jieshi Yu, Zhenyu Wen, Wanke Hu, Mingwang Chen, Yuanlong Zhang, Shasha Liu, Gang Wang, Zhao Wang, Dan Wang, Shao-Lun Zhai, Wen-Kang Wei, Tianyu Li, Ming Liao","doi":"10.1080/22221751.2024.2343907","DOIUrl":"10.1080/22221751.2024.2343907","url":null,"abstract":"<p><p>Influenza D virus (IDV) plays an important role in the bovine respiratory disease (BRD) complex. Its potential for the zoonotic transmission is of particular concern. In China, IDV has previously been identified in agricultural animals by molecular surveys with no live virus isolates reported. In this study, live IDVs were successfully isolated from cattle in China, which prompted us to further investigate the national prevalence, antigenic property, and infection biology of the virus. IDV RNA was detected in 11.1% (51/460) of cattle throughout the country in 2022-2023. Moreover, we conducted the first IDV serosurveillance in China, revealing a high seroprevalence (91.4%, 393/430) of IDV in cattle during the 2022-2023 winter season. Notably, all the 16 provinces from which cattle originated possessed seropositive animals, and 3 of them displayed the 100% IDV-seropositivity rate. In contrast, a very low seroprevalence of IDV was observed in pigs (3%, 3/100) and goats (1%, 1/100) during the same period of investigation. Furthermore, besides D/Yama2019 lineage-like IDVs, we discovered the D/660 lineage-like IDV in Chinese cattle, which has not been detected to date in Asia. Finally, the Chinese IDVs replicated robustly in diverse cell lines but less efficiently in the swine cell line. Considering the nationwide distribution, high seroprevalence, and appreciably genetic diversity, further studies are required to fully evaluate the risk of Chinese IDVs for both animal and human health in China, which can be evidently facilitated by IDV isolates reported in this study.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":13.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial. 口服雾化二价腺病毒5型载体新冠肺炎疫苗和B.1.1.529变异腺病毒5号载体新冠肺炎疫苗对18岁及以上成年人异源增强的安全性和免疫原性:一项随机、双盲、平行对照试验。
IF 13.2 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2023-12-30 DOI: 10.1080/22221751.2023.2281355
Jia-Wei Xu, Bu-Sen Wang, Ping Gao, Hai-Tao Huang, Fei-Yu Wang, Wei Qiu, Yuan-Yuan Zhang, Yu Xu, Jin-Bo Gou, Lin-Ling Yu, Xuan Liu, Rui-Jie Wang, Tao Zhu, Li-Hua Hou, Qing- Wang

Vaccination strategies that can induce a broad spectrum immune response are important to enhance protection against SARS-CoV-2 variants. We conducted a randomized, double-blind and parallel controlled trial to evaluate the safety and immunogenicity of the bivalent (5×1010viral particles) and B.1.1.529 variant (5×1010viral particles) adenovirus type-5 (Ad5) vectored COVID-19 vaccines administrated via inhalation. 451 eligible subjects aged 18 years and older who had been vaccinated with three doses inactivated COVID-19 vaccines were randomly assigned to inhale one dose of either B.1.1.529 variant Ad5 vectored COVID-19 vaccine (Ad5-nCoVO-IH group, N=150), bivalent Ad5 vectored COVID-19 vaccine (Ad5-nCoV/O-IH group, N=151), or Ad5 vectored COVID-19 vaccine (5×1010viral particles; Ad5-nCoV-IH group, N=150). Adverse reactions reported by 37 (24.67%) participants in the Ad5-nCoVO-IH group, 28 (18.54%) in the Ad5-nCoV/O-IH group, and 26 (17.33%) in the Ad5-nCoV-IH group with mainly mild to moderate dry mouth, oropharyngeal pain, headache, myalgia, cough, fever and fatigue. No serious adverse events related to the vaccine were reported. Investigational vaccines were immunogenic, with significant difference in the GMTs of neutralizing antibodies against Omicron BA.1 between Ad5-nCoV/O-IH (43.70) and Ad5-nCoV-IH (29.25) at 28 days after vaccination (P=0.0238). The seroconversion rates of neutralizing antibodies against BA.1 in Ad5-nCoVO-IH, Ad5-nCoV/O-IH, and Ad5-nCoV-IH groups were 56.00%, 59.60% and 48.67% with no significant difference among the groups. Overall, the investigational vaccines were demonstrated to be safe and well tolerated in adults, and was highly effective in inducing mucosal immunities in addition to humoral and cellular immune responses defending against SARS-CoV-2 variants.Trial registration: Chictr.org identifier: ChiCTR2200063996.

可以诱导广谱免疫反应的疫苗接种策略对于增强对严重急性呼吸系统综合征冠状病毒2型变异株的保护非常重要。我们进行了一项随机、双盲和平行对照试验,以评估吸入接种的二价(5×1010病毒颗粒)和B.1.1.529变体(5×1010病毒颗粒)5型腺病毒(Ad5)载体新冠肺炎疫苗的安全性和免疫原性。总共451名18岁及以上接种过三剂新冠肺炎灭活疫苗的合格受试者被随机分配吸入一剂B.1.1.529变体Ad5载体新冠肺炎疫苗(Ad5-nCoVO-IH组,N=150)、二价Ad5载体新冠肺炎疫苗(Ad3-nCoV/O-IH组,N=151)、,或Ad5载体新冠肺炎疫苗(5×1010个病毒颗粒;Ad5-nCoV-IH组,N=150)。主要安全性结果包括Ad5-nCoVO IH组37名(24.67%)参与者、Ad5-nCoV/O-IH组28名(18.54%)参与者和Ad5-nCoV-IH组26名(17.33%)参与者报告的不良反应,主要表现为轻度至中度口干、口咽疼痛、头痛、肌痛、咳嗽、发烧和疲劳。未报告与疫苗相关的严重不良事件。所有研究疫苗都是免疫原性的,在接种后28天,Ad5-nCoV/O-IH(43.70)和Ad5-nCoV IH(29.25)之间的针对奥密克戎BA.1的中和抗体GMT差异具有统计学意义(P=0.0238),59.60%和48.67%,差异无统计学意义。总的来说,研究疫苗在成年人中被证明是安全和耐受性良好的,并且在诱导粘膜免疫以及防御严重急性呼吸系统综合征冠状病毒2型变异株的体液和细胞免疫反应方面非常有效。试验注册:Chictr.org标识符:ChiCTR220063996。
{"title":"Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.","authors":"Jia-Wei Xu, Bu-Sen Wang, Ping Gao, Hai-Tao Huang, Fei-Yu Wang, Wei Qiu, Yuan-Yuan Zhang, Yu Xu, Jin-Bo Gou, Lin-Ling Yu, Xuan Liu, Rui-Jie Wang, Tao Zhu, Li-Hua Hou, Qing- Wang","doi":"10.1080/22221751.2023.2281355","DOIUrl":"10.1080/22221751.2023.2281355","url":null,"abstract":"<p><p>Vaccination strategies that can induce a broad spectrum immune response are important to enhance protection against SARS-CoV-2 variants. We conducted a randomized, double-blind and parallel controlled trial to evaluate the safety and immunogenicity of the bivalent (5×10<sup>10</sup>viral particles) and B.1.1.529 variant (5×10<sup>10</sup>viral particles) adenovirus type-5 (Ad5) vectored COVID-19 vaccines administrated via inhalation. 451 eligible subjects aged 18 years and older who had been vaccinated with three doses inactivated COVID-19 vaccines were randomly assigned to inhale one dose of either B.1.1.529 variant Ad5 vectored COVID-19 vaccine (Ad5-nCoVO-IH group, N=150), bivalent Ad5 vectored COVID-19 vaccine (Ad5-nCoV/O-IH group, N=151), or Ad5 vectored COVID-19 vaccine (5×10<sup>10</sup>viral particles; Ad5-nCoV-IH group, N=150). Adverse reactions reported by 37 (24.67%) participants in the Ad5-nCoVO-IH group, 28 (18.54%) in the Ad5-nCoV/O-IH group, and 26 (17.33%) in the Ad5-nCoV-IH group with mainly mild to moderate dry mouth, oropharyngeal pain, headache, myalgia, cough, fever and fatigue. No serious adverse events related to the vaccine were reported. Investigational vaccines were immunogenic, with significant difference in the GMTs of neutralizing antibodies against Omicron BA.1 between Ad5-nCoV/O-IH (43.70) and Ad5-nCoV-IH (29.25) at 28 days after vaccination (P=0.0238). The seroconversion rates of neutralizing antibodies against BA.1 in Ad5-nCoVO-IH, Ad5-nCoV/O-IH, and Ad5-nCoV-IH groups were 56.00%, 59.60% and 48.67% with no significant difference among the groups. Overall, the investigational vaccines were demonstrated to be safe and well tolerated in adults, and was highly effective in inducing mucosal immunities in addition to humoral and cellular immune responses defending against SARS-CoV-2 variants.Trial registration: Chictr.org identifier: ChiCTR2200063996.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":13.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemic features and megagenomic analysis of childhood Mycoplasma pneumoniae post COVID-19 pandemic: a 6-year study in southern China. COVID-19大流行后儿童肺炎支原体的流行特征和巨基因组分析:华南地区为期 6 年的研究。
IF 8.4 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-27 DOI: 10.1080/22221751.2024.2353298
Yi Xu, Chen Yang, Panpan Sun, Fansen Zeng, Qian Wang, Jianlong Wu, Chunxiao Fang, Che Zhang, Jinping Wang, Yiling Gu, Xiaohuan Wu, Xiaoxian Zhang, Bin Yang, Juhua Yang, Hongwei Zhang, Jiacee Lian, Jinqiu Zhang, Li Huang, Qizhou Lian

With the atypical rise of Mycoplasma pneumoniae infection (MPI) in 2023, prompt studies are needed to determine the current epidemic features and risk factors with emerging trends of MPI to furnish a framework for subsequent investigations. This multicentre, retrospective study was designed to analyse the epidemic patterns of MPI before and after the COVID-19 pandemic, as well as genotypes and the macrolide-resistance-associated mutations in MP sampled from paediatric patients in Southern China. Clinical data was collected from 1,33,674 patients admitted into investigational hospitals from 1 June 2017 to 30 November 2023. Metagenomic next-generation sequencing (mNGS) data were retrieved based on MP sequence positive samples from 299 paediatric patients for macrolide-resistance-associated mutations analysis. Pearson's chi-squared test was used to compare categorical variables between different time frames. The monthly average cases of paediatric common respiratory infection diseases increased without enhanced public health measures after the pandemic, especially for influenza, respiratory syncytial virus infection, and MPI. The contribution of MPI to pneumoniae was similar to that in the outbreak in 2019. Compared to mNGS data between 2019-2022 and 2023, the severity of MP did not grow stronger despite higher rates of macrolide-resistance hypervariable sites, including loci 2063 and 2064, were detected in childhood MP samples of 2023. Our findings indicated that ongoing surveillance is necessary to understand the impact of post pandemic on MP transmission disruption during epidemic season and the severity of clinical outcomes in different scenarios.

随着 2023 年肺炎支原体感染(MPI)的非典型上升,需要及时开展研究以确定当前的流行特征和风险因素以及 MPI 的新趋势,从而为后续研究提供框架。这项多中心回顾性研究旨在分析 COVID-19 大流行前后肺炎支原体感染的流行模式,以及从华南地区儿科患者中抽取的肺炎支原体的基因型和与大环内酯类药物耐药性相关的突变。临床数据收集自2017年6月1日至2023年11月30日期间调查医院收治的133674名患者。根据 299 名儿科患者的 MP 序列阳性样本检索了元基因组新一代测序(mNGS)数据,用于分析大环内酯类药物耐药性相关突变。采用皮尔逊卡方检验比较不同时间段的分类变量。大流行后,在没有加强公共卫生措施的情况下,儿科常见呼吸道感染疾病的月平均病例数有所增加,尤其是流感、呼吸道合胞病毒感染和 MPI。MPI 对肺炎的贡献与 2019 年爆发时相似。与 2019-2022 年和 2023 年的 mNGS 数据相比,尽管在 2023 年的儿童 MP 样本中检测到了更高比例的大环内酯耐药高变异位点,包括位点 2063 和 2064,但 MP 的严重性并未增强。我们的研究结果表明,有必要进行持续监测,以了解大流行后MP传播中断对流行季节的影响以及不同情况下临床结果的严重程度。
{"title":"Epidemic features and megagenomic analysis of childhood <i>Mycoplasma pneumoniae</i> post COVID-19 pandemic: a 6-year study in southern China.","authors":"Yi Xu, Chen Yang, Panpan Sun, Fansen Zeng, Qian Wang, Jianlong Wu, Chunxiao Fang, Che Zhang, Jinping Wang, Yiling Gu, Xiaohuan Wu, Xiaoxian Zhang, Bin Yang, Juhua Yang, Hongwei Zhang, Jiacee Lian, Jinqiu Zhang, Li Huang, Qizhou Lian","doi":"10.1080/22221751.2024.2353298","DOIUrl":"10.1080/22221751.2024.2353298","url":null,"abstract":"<p><p>With the atypical rise of <i>Mycoplasma pneumoniae</i> infection (MPI) in 2023, prompt studies are needed to determine the current epidemic features and risk factors with emerging trends of MPI to furnish a framework for subsequent investigations. This multicentre, retrospective study was designed to analyse the epidemic patterns of MPI before and after the COVID-19 pandemic, as well as genotypes and the macrolide-resistance-associated mutations in <i>MP</i> sampled from paediatric patients in Southern China. Clinical data was collected from 1,33,674 patients admitted into investigational hospitals from 1 June 2017 to 30 November 2023. Metagenomic next-generation sequencing (mNGS) data were retrieved based on <i>MP</i> sequence positive samples from 299 paediatric patients for macrolide-resistance-associated mutations analysis. <i>Pearson's chi-squared test</i> was used to compare categorical variables between different time frames. The monthly average cases of paediatric common respiratory infection diseases increased without enhanced public health measures after the pandemic, especially for influenza, respiratory syncytial virus infection, and MPI. The contribution of MPI to pneumoniae was similar to that in the outbreak in 2019. Compared to mNGS data between 2019-2022 and 2023, the severity of <i>MP</i> did not grow stronger despite higher rates of macrolide-resistance hypervariable sites, including loci 2063 and 2064, were detected in childhood <i>MP</i> samples of 2023. Our findings indicated that ongoing surveillance is necessary to understand the impact of post pandemic on <i>MP</i> transmission disruption during epidemic season and the severity of clinical outcomes in different scenarios.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection and phylogenetic analysis of contemporary H14N2 Avian influenza A virus in domestic ducks in Southeast Asia (Cambodia). 东南亚(柬埔寨)家鸭中当代 H14N2 甲型禽流感病毒的检测和系统发育分析。
IF 13.2 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2024-04-17 DOI: 10.1080/22221751.2023.2297552
Jurre Y Siegers, Michelle Wille, Sokhoun Yann, Songha Tok, Sarath Sin, Sokha Chea, Alice Porco, Sreyem Sours, Vutha Chim, Samban Chea, Kimtuo Chhel, Sothyra Tum, San Sorn, Makara Hak, Peter Thielen, Vijaykrishna Dhanasekaran, Erik A Karlsson

Avian influenza virus (AIV) in Asia is a complex system with numerous subtypes and a highly porous wild birds-poultry interface. Certain AIV subtypes, such as H14, are underrepresented in current surveillance efforts, leaving gaps in our understanding of their ecology and evolution. The detection of rare subtype H14 in domestic ducks in Southeast Asia comprises a geographic region and domestic bird population previously unassociated with this subtype. These H14 viruses have a complex evolutionary history involving gene reassortment events. They share sequence similarity to AIVs endemic in Cambodian ducks, and Eurasian low pathogenicity and high pathogenicity H5Nx AIVs. The detection of these H14 viruses in Southeast Asian domestic poultry further advances our knowledge of the ecology and evolution of this subtype and reinforces the need for continued, longitudinal, active surveillance in domestic and wild birds. Additionally, in vivo and in vitro risk assessment should encompass rare AIV subtypes, as they have the potential to establish in poultry systems.

摘要 亚洲的禽流感病毒(AIV)是一个复杂的系统,有许多亚型,野禽与家禽之间的联系非常松散。某些 AIV 亚型(如 H14)在目前的监测工作中代表性不足,使我们对其生态学和进化的了解存在差距。在东南亚的家鸭中检测到罕见的 H14 亚型病毒,而该地区和家禽种群以前从未与该亚型病毒有关联。这些 H14 病毒有着复杂的进化史,涉及基因重组事件。它们与柬埔寨鸭子中流行的甲型禽流感病毒以及欧亚低致病性和高致病性 H5Nx 甲型禽流感病毒序列相似。在东南亚家禽中检测到这些 H14 病毒进一步增进了我们对该亚型的生态学和进化的了解,并加强了对家禽和野生鸟类进行持续、纵向和积极监测的必要性。此外,体内和体外风险评估应包括罕见的 AIV 亚型,因为它们有可能在家禽系统中建立。
{"title":"Detection and phylogenetic analysis of contemporary H14N2 Avian influenza A virus in domestic ducks in Southeast Asia (Cambodia).","authors":"Jurre Y Siegers, Michelle Wille, Sokhoun Yann, Songha Tok, Sarath Sin, Sokha Chea, Alice Porco, Sreyem Sours, Vutha Chim, Samban Chea, Kimtuo Chhel, Sothyra Tum, San Sorn, Makara Hak, Peter Thielen, Vijaykrishna Dhanasekaran, Erik A Karlsson","doi":"10.1080/22221751.2023.2297552","DOIUrl":"10.1080/22221751.2023.2297552","url":null,"abstract":"<p><p>Avian influenza virus (AIV) in Asia is a complex system with numerous subtypes and a highly porous wild birds-poultry interface. Certain AIV subtypes, such as H14, are underrepresented in current surveillance efforts, leaving gaps in our understanding of their ecology and evolution. The detection of rare subtype H14 in domestic ducks in Southeast Asia comprises a geographic region and domestic bird population previously unassociated with this subtype. These H14 viruses have a complex evolutionary history involving gene reassortment events. They share sequence similarity to AIVs endemic in Cambodian ducks, and Eurasian low pathogenicity and high pathogenicity H5Nx AIVs. The detection of these H14 viruses in Southeast Asian domestic poultry further advances our knowledge of the ecology and evolution of this subtype and reinforces the need for continued, longitudinal, active surveillance in domestic and wild birds. Additionally, <i>in vivo</i> and <i>in vitro</i> risk assessment should encompass rare AIV subtypes, as they have the potential to establish in poultry systems.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":13.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138795446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium. 异源 mRNA/MVA 提供三聚体-RBD 作为预防 SARS-CoV-2 的有效疫苗方案:COVARNA 联盟。
IF 8.4 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-08 DOI: 10.1080/22221751.2024.2387906
Laura Marcos-Villar, Beatriz Perdiguero, María López-Bravo, Carmen Zamora, Laura Sin, Enrique Álvarez, Carlos Óscar S Sorzano, Pedro J Sánchez-Cordón, José M Casasnovas, David Astorgano, Juan García-Arriaza, Shubaash Anthiya, Mireya L Borrajo, Gustavo Lou, Belén Cuesta, Lorenzo Franceschini, Josep L Gelpí, Kris Thielemans, Marta Sisteré-Oró, Andreas Meyerhans, Felipe García, Ignasi Esteban, Núria López-Bigas, Montserrat Plana, María J Alonso, Mariano Esteban, Carmen Elena Gómez

Despite the high efficiency of current SARS-CoV-2 mRNA vaccines in reducing COVID-19 morbidity and mortality, waning immunity and the emergence of resistant variants underscore the need for novel vaccination strategies. This study explores a heterologous mRNA/Modified Vaccinia virus Ankara (MVA) prime/boost regimen employing a trimeric form of the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein compared to a homologous MVA/MVA regimen. In C57BL/6 mice, the RBD was delivered during priming via an mRNA vector encapsulated in nanoemulsions (NE) or lipid nanoparticles (LNP), followed by a booster with a replication-deficient MVA-based recombinant virus (MVA-RBD). This heterologous mRNA/MVA regimen elicited strong anti-RBD binding and neutralizing antibodies (BAbs and NAbs) against both the ancestral SARS-CoV-2 strain and different variants of concern (VoCs). Additionally, this protocol induced robust and polyfunctional RBD-specific CD4 and CD8 T cell responses, particularly in animals primed with mLNP-RBD. In K18-hACE2 transgenic mice, the LNP-RBD/MVA combination provided complete protection from morbidity and mortality following a live SARS-CoV-2 challenge compared with the partial protection observed with mNE-RBD/MVA or MVA/MVA regimens. Although the mNE-RBD/MVA regimen only protects half of the animals, it was able to induce antibodies with Fc-mediated effector functions besides NAbs. Moreover, viral replication and viral load in the respiratory tract were markedly reduced and decreased pro-inflammatory cytokine levels were observed. These results support the efficacy of heterologous mRNA/MVA vaccine combinations over homologous MVA/MVA regimen, using alternative nanocarriers that circumvent intellectual property restrictions of current mRNA vaccine formulations.

尽管目前的 SARS-CoV-2 mRNA 疫苗在降低 COVID-19 发病率和死亡率方面具有很高的效率,但免疫力的下降和抗药性变种的出现凸显了新型疫苗接种策略的必要性。本研究探讨了一种异源 mRNA/改良安卡拉疫苗(MVA)的原体/增强方案,该方案采用了 SARS-CoV-2 棘波(S)蛋白受体结合域(RBD)的三聚体形式,并与同源 MVA/MVA 方案进行了比较。在 C57BL/6 小鼠中,RBD 通过封装在纳米乳剂(NE)或脂质纳米颗粒(LNP)中的 mRNA 载体在启动过程中递送,然后用复制缺陷的 MVA 重组病毒(MVA-RBD)进行强化。这种异源 mRNA/MVA 方案可针对 SARS-CoV-2 祖毒株和不同的相关变异株(VoCs)激发强效的抗 RBD 结合抗体和中和抗体(BAbs 和 NAbs)。此外,该方案还能诱导强大的多功能 RBD 特异性 CD4 和 CD8 T 细胞反应,尤其是在使用 mLNP-RBD 的动物中。在 K18-hACE2 转基因小鼠中,与 mNE-RBD/MVA 或 MVA/MVA 方案观察到的部分保护相比,LNP-RBD/MVA 组合可在活体 SARS-CoV-2 挑战后提供完全的发病和死亡保护。虽然 mNE-RBD/MVA 方案只能保护一半的动物,但它除了能诱导 NAbs 外,还能诱导具有 Fc 媒介效应功能的抗体。此外,呼吸道中的病毒复制和病毒载量明显减少,促炎细胞因子水平也有所下降。这些结果表明,异源 mRNA/MVA 疫苗组合比同源 MVA/MVA 方案更有效,其使用的替代纳米载体规避了当前 mRNA 疫苗配方的知识产权限制:试验注册:ClinicalTrials.gov identifier:NCT05226390.
{"title":"Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.","authors":"Laura Marcos-Villar, Beatriz Perdiguero, María López-Bravo, Carmen Zamora, Laura Sin, Enrique Álvarez, Carlos Óscar S Sorzano, Pedro J Sánchez-Cordón, José M Casasnovas, David Astorgano, Juan García-Arriaza, Shubaash Anthiya, Mireya L Borrajo, Gustavo Lou, Belén Cuesta, Lorenzo Franceschini, Josep L Gelpí, Kris Thielemans, Marta Sisteré-Oró, Andreas Meyerhans, Felipe García, Ignasi Esteban, Núria López-Bigas, Montserrat Plana, María J Alonso, Mariano Esteban, Carmen Elena Gómez","doi":"10.1080/22221751.2024.2387906","DOIUrl":"10.1080/22221751.2024.2387906","url":null,"abstract":"<p><p>Despite the high efficiency of current SARS-CoV-2 mRNA vaccines in reducing COVID-19 morbidity and mortality, waning immunity and the emergence of resistant variants underscore the need for novel vaccination strategies. This study explores a heterologous mRNA/Modified Vaccinia virus Ankara (MVA) prime/boost regimen employing a trimeric form of the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein compared to a homologous MVA/MVA regimen. In C57BL/6 mice, the RBD was delivered during priming via an mRNA vector encapsulated in nanoemulsions (NE) or lipid nanoparticles (LNP), followed by a booster with a replication-deficient MVA-based recombinant virus (MVA-RBD). This heterologous mRNA/MVA regimen elicited strong anti-RBD binding and neutralizing antibodies (BAbs and NAbs) against both the ancestral SARS-CoV-2 strain and different variants of concern (VoCs). Additionally, this protocol induced robust and polyfunctional RBD-specific CD4 and CD8 T cell responses, particularly in animals primed with mLNP-RBD. In K18-hACE2 transgenic mice, the LNP-RBD/MVA combination provided complete protection from morbidity and mortality following a live SARS-CoV-2 challenge compared with the partial protection observed with mNE-RBD/MVA or MVA/MVA regimens. Although the mNE-RBD/MVA regimen only protects half of the animals, it was able to induce antibodies with Fc-mediated effector functions besides NAbs. Moreover, viral replication and viral load in the respiratory tract were markedly reduced and decreased pro-inflammatory cytokine levels were observed. These results support the efficacy of heterologous mRNA/MVA vaccine combinations over homologous MVA/MVA regimen, using alternative nanocarriers that circumvent intellectual property restrictions of current mRNA vaccine formulations.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11313003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity. 全球视角下的猴痘天花疫苗:关于有效性、保护性、安全性和交叉免疫原性的综合元分析和系统回顾。
IF 8.4 2区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-16 DOI: 10.1080/22221751.2024.2387442
Hao Liu, Wenjing Wang, Yang Zhang, Fuchun Wang, Junyi Duan, Tao Huang, Xiaojie Huang, Tong Zhang

A large outbreak of monkeypox occurred in 2022, and most people lack immunity to orthopoxvirus. Smallpox vaccination is essential for preventing further smallpox outbreaks. This study evaluated the effectiveness, protection, safety, and cross-immunogenicity of smallpox vaccine in preventing monkeypox infection. PubMed, Embase, Scopus, and Web of Science were searched from database inception to 10 March 2024. We included studies involving "monkeypox virus" and "vaccinations", and excluded reviews, animal studies, and articles with missing or duplicate data. A total of 37 studies with 57,693 participants were included in the final analysis. The effectiveness data showed that monkeypox infection rates were lower in the smallpox-vaccinated group than in the unvaccinated group (risk ratio [RR]: 0.46; 95% confidence interval [CI]: 0.31-0.68). The protection data showed that smallpox vaccination effectively reduced the risk of severe monkeypox infection (RR: 0.61; 95% CI: 0.42-0.87). Third-generation vaccines showed greater efficacy (RR: 0.36, 95% CI: 0.22-0.56) than first-generation vaccines. The number of doses of smallpox vaccine has no significant effect on monkeypox. Safety data showed that adverse reactions after smallpox vaccination were mainly mild and included local erythema, swelling, induration, itching, and pain. Meanwhile, we found that smallpox vaccination could induce the production of neutralizing antibodies against monkeypox. Our findings offer compelling evidence supporting the clinical application of the smallpox vaccine for preventing monkeypox and advocate that high-risk groups should be prioritized for receiving one dose of the smallpox vaccine if the vaccine stockpile is low.

摘要 2022 年爆发了大规模的猴痘疫情,大多数人对正痘病毒缺乏免疫力。接种天花疫苗对于防止天花进一步爆发至关重要。本研究评估了天花疫苗预防猴痘感染的有效性、保护性、安全性和交叉免疫原性。我们检索了 PubMed、Embase、Scopus 和 Web of Science 数据库中从开始到 2024 年 3 月 10 日的内容。我们纳入了涉及 "猴痘病毒 "和 "疫苗接种 "的研究,并排除了综述、动物研究以及数据缺失或重复的文章。最终分析共纳入了 37 项研究,参与人数达 57,693 人。有效性数据显示,接种天花疫苗组的猴痘感染率低于未接种组(风险比[RR]:0.46;95%置信区间[CI]:0.31-0.68)。保护数据显示,接种天花疫苗可有效降低严重猴痘感染的风险(RR:0.61;95% 置信区间:0.42-0.87)。与第一代疫苗相比,第三代疫苗的效力更高(RR:0.36,95% CI:0.22-0.56)。接种天花疫苗的剂量对猴痘没有明显影响。安全性数据显示,接种天花疫苗后的不良反应主要是轻微的,包括局部红斑、肿胀、压痕、瘙痒和疼痛。同时,我们发现接种天花疫苗可诱导产生针对猴痘的中和抗体。我们的研究结果为临床应用天花疫苗预防猴痘提供了有力的证据,并提倡在疫苗储备不足的情况下,高危人群应优先接种一剂天花疫苗。
{"title":"Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity.","authors":"Hao Liu, Wenjing Wang, Yang Zhang, Fuchun Wang, Junyi Duan, Tao Huang, Xiaojie Huang, Tong Zhang","doi":"10.1080/22221751.2024.2387442","DOIUrl":"10.1080/22221751.2024.2387442","url":null,"abstract":"<p><p>A large outbreak of monkeypox occurred in 2022, and most people lack immunity to orthopoxvirus. Smallpox vaccination is essential for preventing further smallpox outbreaks. This study evaluated the effectiveness, protection, safety, and cross-immunogenicity of smallpox vaccine in preventing monkeypox infection. PubMed, Embase, Scopus, and Web of Science were searched from database inception to 10 March 2024. We included studies involving \"monkeypox virus\" and \"vaccinations\", and excluded reviews, animal studies, and articles with missing or duplicate data. A total of 37 studies with 57,693 participants were included in the final analysis. The effectiveness data showed that monkeypox infection rates were lower in the smallpox-vaccinated group than in the unvaccinated group (risk ratio [RR]: 0.46; 95% confidence interval [CI]: 0.31-0.68). The protection data showed that smallpox vaccination effectively reduced the risk of severe monkeypox infection (RR: 0.61; 95% CI: 0.42-0.87). Third-generation vaccines showed greater efficacy (RR: 0.36, 95% CI: 0.22-0.56) than first-generation vaccines. The number of doses of smallpox vaccine has no significant effect on monkeypox. Safety data showed that adverse reactions after smallpox vaccination were mainly mild and included local erythema, swelling, induration, itching, and pain. Meanwhile, we found that smallpox vaccination could induce the production of neutralizing antibodies against monkeypox. Our findings offer compelling evidence supporting the clinical application of the smallpox vaccine for preventing monkeypox and advocate that high-risk groups should be prioritized for receiving one dose of the smallpox vaccine if the vaccine stockpile is low.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":8.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of highly pathogenic avian influenza A (H5N1) viruses isolated from cats in South Korea, 2023. 韩国2023年从猫中分离的高致病性禽流感A (H5N1)病毒的特征
IF 13.2 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2024-01-22 DOI: 10.1080/22221751.2023.2290835
Kyungmoon Lee, Minjoo Yeom, Thi Thu Hang Vu, Hai-Quynh Do, Woonsung Na, Mikyung Lee, Dae Gwin Jeong, Doo-Sung Cheon, Daesub Song
{"title":"Characterization of highly pathogenic avian influenza A (H5N1) viruses isolated from cats in South Korea, 2023.","authors":"Kyungmoon Lee, Minjoo Yeom, Thi Thu Hang Vu, Hai-Quynh Do, Woonsung Na, Mikyung Lee, Dae Gwin Jeong, Doo-Sung Cheon, Daesub Song","doi":"10.1080/22221751.2023.2290835","DOIUrl":"10.1080/22221751.2023.2290835","url":null,"abstract":"","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":13.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10810616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138477042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Viral diversity in wild and urban rodents of Yunnan Province, China. 云南省野生鼠类和城市鼠类的病毒多样性。
IF 13.2 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2024-01-30 DOI: 10.1080/22221751.2023.2290842
Yakhouba Kane, Alexander Tendu, Ruiya Li, Yanhua Chen, Emilio Mastriani, Jiaming Lan, Alice Catherine Hughes, Nicolas Berthet, Gary Wong

Rodents represent over 40% of known mammal species and are found in various terrestrial habitats. They are significant reservoirs for zoonotic viruses, including harmful pathogens such as arenaviruses and hantaviruses, yet knowledge of their hosts and distributions is limited. Therefore, characterizing the virome profile in these animals is invaluable for outbreak preparedness, especially in potential hotspots of mammal diversity. This study included 681 organs from 124 rodents and one Chinese tree shrew collected from Yunnan Province, China, during 2020-2021. Metagenomic analysis revealed unique features of mammalian viruses in rodent organs across habitats with varying human disturbances. R. tanezumi in locations with high anthropogenic disturbance exhibited the highest mammal viral diversity, with spleen and lung samples showing the highest diversities for these viruses at the organ level. Mammal viral diversity for both commensal and non-commensal rats was identified to positively correlate with landscape disturbance. Some virus families were associated with particular organs or host species, suggesting tropism for these pathogens. Notably, known and novel viral species that are likely to infect humans were identified. R. tanezumi was identified as a reservoir and carrier for various zoonotic viruses, including porcine bocavirus, hantavirus, cardiovirus, and lyssavirus. These findings highlight the influence of rodent community composition and anthropogenic activities on diverse virome profiles, with R. tanezumi as an important reservoir for zoonotic viruses.

啮齿类动物占已知哺乳动物种类的40%以上,分布在各种陆地栖息地。它们是人畜共患病毒(包括沙粒病毒和汉坦病毒等有害病原体)的重要宿主,但对其宿主和分布的了解有限。因此,确定这些动物的病毒组特征对于疫情防范,特别是在哺乳动物多样性的潜在热点地区,是非常宝贵的。本研究包括2020-2021年在中国云南省收集的124只啮齿动物和1只中国树鼩的681个器官。宏基因组分析揭示了不同人类干扰生境中啮齿动物器官中哺乳动物病毒的独特特征。在人为干扰程度高的地区,黄胸鼠的病毒多样性最高,脾脏和肺部的病毒多样性最高。哺乳动物病毒多样性与景观干扰呈显著正相关。一些病毒科与特定的器官或宿主物种有关,表明这些病原体具有趋向性。值得注意的是,确定了可能感染人类的已知和新型病毒物种。tanezumi被确定为多种人畜共患病毒的储存库和载体,包括猪bocavavirus、汉坦病毒、心脏病毒和溶血病毒。这些发现强调了啮齿动物群落组成和人为活动对多种病毒谱的影响,认为黄尾鼠是人畜共患病毒的重要储存库。
{"title":"Viral diversity in wild and urban rodents of Yunnan Province, China.","authors":"Yakhouba Kane, Alexander Tendu, Ruiya Li, Yanhua Chen, Emilio Mastriani, Jiaming Lan, Alice Catherine Hughes, Nicolas Berthet, Gary Wong","doi":"10.1080/22221751.2023.2290842","DOIUrl":"10.1080/22221751.2023.2290842","url":null,"abstract":"<p><p>Rodents represent over 40% of known mammal species and are found in various terrestrial habitats. They are significant reservoirs for zoonotic viruses, including harmful pathogens such as arenaviruses and hantaviruses, yet knowledge of their hosts and distributions is limited. Therefore, characterizing the virome profile in these animals is invaluable for outbreak preparedness, especially in potential hotspots of mammal diversity. This study included 681 organs from 124 rodents and one Chinese tree shrew collected from Yunnan Province, China, during 2020-2021. Metagenomic analysis revealed unique features of mammalian viruses in rodent organs across habitats with varying human disturbances. <i>R. tanezumi</i> in locations with high anthropogenic disturbance exhibited the highest mammal viral diversity, with spleen and lung samples showing the highest diversities for these viruses at the organ level. Mammal viral diversity for both commensal and non-commensal rats was identified to positively correlate with landscape disturbance. Some virus families were associated with particular organs or host species, suggesting tropism for these pathogens. Notably, known and novel viral species that are likely to infect humans were identified. <i>R. tanezumi</i> was identified as a reservoir and carrier for various zoonotic viruses, including porcine bocavirus, hantavirus, cardiovirus, and lyssavirus. These findings highlight the influence of rodent community composition and anthropogenic activities on diverse virome profiles, with <i>R. tanezumi</i> as an important reservoir for zoonotic viruses.</p>","PeriodicalId":11602,"journal":{"name":"Emerging Microbes & Infections","volume":null,"pages":null},"PeriodicalIF":13.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10829829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138477057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Emerging Microbes & Infections
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1